Peptides · Gastric pentadecapeptide (body protection compound)

BPC-157: what the studies show

Every line below comes from a study, label or regulator record, checked by two models, with the source linked. Information, not medical advice. For adults 18+.

What it is

BPC-157 is a 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) based on a sequence first reported from human gastric juice. It is also called PL 14736 or bepecin.^[1]^[2]^[3]
No approved drug contains BPC-157 in any country, and it is not in the European, Japanese or International Pharmacopeias (FDA briefing document, evaluation dated 2026-05-11).^[3]
Products sold online or by compounding pharmacies are made by chemical synthesis. USADA says it is prohibited in sport under the WADA S0 category (non-approved substances).^[4]

Bottom line

BPC-157 has been tested almost only in rats and mice, and much of that work comes from one research group. Controlled human data are essentially absent: a 2005 ulcerative colitis trial known only as a meeting abstract, a small knee-pain chart review, and a two-person IV safety pilot. Whether it works or is safe in people is not established.^[5]^[3]^[6]^[7]

What the human studies found

FDA's reviewers found one human efficacy trial: a multicentre, randomised, double-blind trial of 53 adults with mild-to-moderate ulcerative colitis given an 80 mg BPC-157 enema or placebo once daily for 2 weeks (Ruenzi 2005, meeting abstract only). The disease score fell by 3.2 points with BPC-157 and 1.6 with placebo, and the difference between groups was 1.6 points with a 95% CI of -4.84 to 1.62, so it did not exclude no effect. FDA called the data inadequate to support efficacy or safety.^[3]
A retrospective chart review at one private clinic in Florida covered 17 people given BPC-157 (alone or with thymosin beta-4) as a knee injection. Of 16 reached by phone, 14 reported pain relief. There was no control group, no validated outcome tool, and recall was by phone 6 to 12 months later.^[6]
A 2025 pilot in 2 adults (ages 58 and 68, both previous users) gave 10 mg and then 20 mg BPC-157 by IV infusion over one hour on consecutive days. The authors reported no change in heart, liver, kidney, thyroid or glucose blood tests and no side effects. Two people over 3 days cannot establish safety.^[7]
A trial registered for 2027 (NCT07803250, not yet recruiting, phase 1, 30 planned participants) will test daily subcutaneous BPC-157 for 90 days after rotator cuff repair. Its own description says BPC-157 has not undergone formal human clinical trials.^[8]
A 2025 systematic review of the orthopaedic literature found 36 studies: 35 preclinical and 1 clinical (the knee injection chart review, reported there as 7 of 12 patients with relief for more than 6 months). It found no clinical safety data. Although this record is labelled a meta-analysis (grade A) in the records we hold, it is a review of mostly animal studies and not human evidence of that strength.^[5]

Known risks and side effects

Human safety data are almost absent. FDA's reviewers found no studies of oral, subcutaneous, nasal or skin use in people, and only two rectal-enema studies of up to 2 weeks that reported no serious adverse events with limited safety monitoring. They said there is no information on BPC-157 pharmacokinetics in humans.^[3]
Reports to FDA's adverse event system (FAERS) included injection site reaction, shortness of breath, and gum and skin darkening. FDA said it was unclear whether BPC-157 caused them.^[3]
FDA flagged a risk of immune reactions (immunogenicity) for injected and nasal peptides because of aggregation and impurities. FDA did not find carcinogenicity or full reproductive toxicity studies for the nominated routes.^[3]^[9]
In animals, a published preclinical package (mice, rats, rabbits, dogs) found no serious toxicity. One dog finding was a lower creatinine at 2 mg/kg that recovered after 2 weeks off drug. In rats and dogs, intramuscular bioavailability was about 14 to 19% in rats and 45 to 51% in dogs, and half-life was under 30 minutes.^[10]^[1]
Quality of product sold online is unknown. A review of the orthopaedic literature warns of unregulated manufacturing and contamination.^[5]

Legal status

As of 2026-10-09, BPC-157 is not approved by FDA. FDA's category 2 page lists BPC-157 among substances nominated but withdrawn that were previously in category 2 (significant safety risks), citing immunogenicity risk and limited safety information.^[9]
FDA's briefing document for the July 23-24, 2026 advisory committee (dated 2026-05-11) proposed not adding BPC-157 (free base or acetate) to the 503A bulks list. It judged the substance not well characterised, found a lack of evidence of effectiveness for ulcerative colitis, and found insufficient safety information.^[3]
ABC News reportedly said the committee narrowly voted to recommend adding BPC-157 and five other peptides to the 503A list, against the FDA staff view. This is a secondary report. As of 2026-10-09 FDA had not posted minutes. The vote is advisory and non-binding, and FDA must still review it and publish a proposed rule.^[11]